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1. Introduction
This paper aims at evaluating the (stochastic) life
time of a subject confronted with the possibility of develop-
ing a chronic noncommuni.cable disease, such as cardiovascular
d.íseast:; and cancc~r. 'i'o this encl expectc~d lj Ee t ime and ex-
pected utility of life time are used. These measures arc p.1an-
ned to be used in evaluating a so called intervention program
aimed at reducing the incidence of the disease.
In Section 2 the illness-death model, used to des-
cribe the various states from a disease free state towards the
final state of death, is presented. Section 3 is concerned
with life expectancy and a decomposition of life expectancy
which is useful for evaluating an intervention program. In
Section 4 form and construction of an individual utility func-
tion are discussed. Also in Section 4 the actual computation
of expected utility is presented. Section 5 formulates the
problem of when and how to intervene as a problem of maximiz-
ing expected utility.
2. T}ie illness-death model
At any ti.me the subject considered is in one of the
mutually exclusive states of Figure 1.
F'igure 1. The illness-death model.
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The subject is either dead or alive. In the latter case he is
in one of the following two states:
state H: the disease free ("health") state, which
applies if the disease has as yet not de-
ve loped;
titate D: thf~ staLr~ of chronic disease, whirh applies
,is suuii as t.lic, diseasc starts to develoE~.
6Jheii !he sub~ec:t ciics, he dies either from the disease or
from other causes. In the latter case he was either in state
Fi or in state D, previous to the time of his death. Hence the
following mortality states are considered:
state M1: the state of mortality caused by the
disease;
state M2: the state of mortality caused by other
diseases, which is reached from states H
or D.
It remains to specify the failure rate functions of
the competing risks. Time x is supposed to coincide with age.
The disease free state H can be left as a result of two com-
peting risk causes: either the start of the disease with rate
?,l(x), or mortality from other diseases with rate a1(x). Re-
turn to the disease free state H is impossible. The disease
state D can also be left as a result of two competing risk
causes: either mortality from the disease with rate ul(x-t),
with t the starting time of the disease, or mortality from
other diseases with rate u2(x).
This completes the description of the illness-death
process. Similar models may be found in Sacks and Chiang
(1977), Sander (1978) and Beck (1979). Zn the next section
the expected life time for this model and a relevant decompo-
sition of expected life time is presented.
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3. Life ex~ectancy and its decomposition
Life expectancy is equal to the weighted mean of
life expectancy given the subject considered develops the
disease and of life expectancy given the subject does not de-
velop the disease, with weights nl and n2 - 1-nl, where r.l is
the probability that the subject develops the disease and n2
is the probability that the subject dies from other diseases.
Lífe expectancv, given no development of the disease,
is calculated as follows. Let FH(x) denote the so called sur-
vival function for the disease free state H, i.e. FH(x) is
the probability that the subject considered is (survives) in
state H at time x. FH(x) can be expressed in the parameters
al and ,a2 as follows:
r.
( 3. l ) Fif ( x) - exp ( -I f a 1 (y) f ~2 (y) }dy] .
0
The conditional density function of time x, given "failure"
from cause j(j - 1,2), is:
a . (x)F (x)
(3.2) fj(x) - --~-n.li (j - 1,2);
J
see e.g. David and Moeschberger (1978) and Kalbfleisch and
Prentice (1980). Evidently nj equals:
(3.3) ,cj - ó ~j(x)FEI(x)dx (j - 1,2).
Life expeetancy, given no development of the disease, to be
denoted by E(X~2), is equal to:
(3.4) E(X~2) - ;' x f2(x)dx.
0
Life expectancy, given (development of) the di.sease,
equals the sum of life expectancy in the health state H given
the dísease and life expectancy in the disease state D. Life
expectancy in state H, given development of the disease, de-
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noted as E(,X;1), equals:
(3.5) E(X; 1) - ~ x fl (x)dx.
0





where g(z~x) is the conditional density function of z, life
time with the discase, given that x is the starting time of
the disease. This conditional density is derived from FD(z~x),
the conditional survival function for the disease state D,
given x as starting time of the disease. Analogously to (3.1),
FD(zjx) is expressed as follows:
z
(3.7) FD(z~x) - exp [--~(ul (y) f u2(~fY) }dyi .
0
From (3.7) one derives g(z~x) as -dFD~dz:
(3.8) g(z~x) - {ul(z) t u2(xfz)}FD(z~x).
Life expectancy, given development of the disease, thus is
the sum of (3.5) and (3.6).
Life expectancy E thus equals:
(3.9) E- n~{E(X~1) f E(Z)} t(1-nl)E(XI2),
with E(X~1), E(X~2) and E(Z) defined in (3.5), (3.4) and (3.6).
The decomposition of E in the right hand side of (3.9),
illustratec in Figure 2, is useful ïor e~~aluatina so called
intervention programs aiming at reductinc the incidence
~i the disease, al(x). It clearly shoo:s the several c~ossible
effects to intervention: a change in al, induced by maninu-
lating its influencinr variables (see Kalbfleisch and Prentice
(1980)) results in chanaes in the disease probability ,rl and





l.iyure 2. Decomposition of liL-e expectancy.
~. Expected utilitY
time (age)
Life expectancy E is one evaluation parameter for
the illness-death process. It does not define uniquely all
situations of an illness-death process between which a subject
may be indifferent. For instance, a second process with a
higher value of E(X~2), that is exactly cancelled out by a
lower value of E(Z), produces the same value of E, while it
is reasonable to assume that this second process is preferred
by the subject over the first process. As the subject is
f.acing chancles, induced by intervention, of Ihe stochastic
illncss-deat.h )~rocess, the "r.atiotial" subject would nol only
look at expccted life time, but also take the more general
approach of calculating expected utilities of life times of
two different processes.
A particular illness-death process can be described
by the following joint density function of the triplet (X,W,J),
with X desease free life time, W disease duration and J an
indicator for the disease, having the value 1 if the disease
develops and 2 if not:
(4.1) h(x,w,j) - nlfl(x)g(w~x) for x~ 0, w~ 0, j- 1
- (1-nl)f2(x) for x~ 0, w- 0, j- 2
- 0 otherwise,
n2 (non disease mortality)
disease death - time (age)
E(X~1) E(X;1)tE(Z)
as follows from the previous section. The random variable W
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coïncides with the random variable Z of the previous section
except that for w- 0 there is a probability mass of 1-nl.
The parameters al, ~2, ul and ~2 determine h(x,w,j).
The subject is assumed to evaluate changes in h(x,w,j),
induced for example by certain intervention measures, by means
of his expected utility of the triplet (X,W,J). The utility
function U is defined as u(x) for a disease free life time of
x time units and as v'(x,w) for a life time in which the
disease starts to develop at time x and lasts for w time units.
So formally U is defined as:
(4.2) U(x,w,j) - (j-1)u(x) t (2-j)v' (x,w).
Expected utility equals:
(4.3) E{U(X,W,J)} - (1-nl)E{,1(X)~J - 2} f n1E{v'(X,W)~J-1}.
For the sequel v'(x,w) is assumed to be as follows:
(4.4) v'(x,w) - u(x) t v(x,w)
i.e, the utility of a life time w with the disease, which
started at time x, may be separately added to the utility of
the disease free time of life. The utility function then be-
comes :
(4.5) U(x,w,j) - u(x) f (2-j)v(x,w),
with expectation:
(4.6) E{U(X,W,J)} - E{u(X)} f n1E{v(X,W)~J - 1}.
Using (4.1) in (4.6) gives:
(4.7) E(U) - !u(x){nlfl(x) t (1-nl)f2(x)}dx f
0
f nl ~ ~v(x,z)fl(x)g(z~x)dx dz,
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which for computational purposes may be rewritten as:
(4.8) E(U) - -~ u(x)dF - ~ a (x)F (x) (Í v(x,z)dF (z~x) }dx.p H Ó 1 H 0 D
Integrating (4.8) by parts results in:
(4.9) E(U) - ó uxFH(x)dx f! al(x)FH(x){ó vzFD(z~x)dz}dx,
where ux - du~dx and vZ -"dv~az are marginal utilities and
where it has been assumed that u(x)FH(x) -~ 0 as x~ m and
v(x,z)FD(z~x) - 0 as z ~ ~.
The usefulness of (9.9) will become clear after more has been
said about the specification of u(x) and v(x,r).
In order to specify the utility function further, it
is supposed that the subject is able to compare his various
health conditions. Two assumedly independent types of health
conditions are distinyuished: a general health condition re-
lated to all kinds of diseases other than the one considered
and a(disease) specific health condition. The subject is
supposedly able to compare his general health condition at one
age with that at another age, and to compare his specific
health condi.tion with the general health condition for any
yiven aeae and disease duration.
Let c;(y) denote the c~eneral health-index at age y.
q(y) assumcdly is a non-negative number, that is equal to 1
at a e ~y y of maximal general health condition. The function
q(y) can be determined from the subject's stated indifference
between one unit of life time at age y(without the disease)
and q(y)~q(y~) - q(y) units of life time at age y~, for all
pairs (y,y~). The subject's use for a life time x without the
disease is by reasonable assumption equal to the sum (integral)
of his successive health conditions, starting from time 0
(which generally is not hís time of birth):
x(4.10) u(x) - ó q(y)dy.
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dx - q(x) .
Further, let qD(y) denote the specific health index
for a subject already having the disease for a time period
of y. Wíthout loss of generality, it is assumed that qD(y)
has a maximum of 1. The time x of the start of the disease is
introduced as follows. The general health condition at time
xty is represented by the value q(xty), which value is assum-
ed to act multiplicatively on q~(y) in order to produce the
overall health index at time xty, with value q(xfy)qp(y). The
subject's use for a life time z with the disease, which start-
ed at time x, is by assumption equal to the sum (integral) of
his successive overall health conditions, starting from time
x:
z
(4.12) v(x,z) - ó q(xfy)qD(y)dy.
With t.his construction of v(x,z) it follows that:
(4.13) av(~ZZ) - q(xtz)qD(z).
Returning to E(U) in (4.9), it is seen that, given
the above construction of u(x) and v(x,z), ux and vz in (4.9)
may be replaced by (4.11) and (4.13), respectively.
The special case q(x) - qD(z) - 1, meaning that the
subject experiences constant marginal utilities, so that
u(x) - x and v(x,z) - z, specifies the case of the previous
section, i.e. life expectancy E; see (4.7). In order to com-
pute E numerically one may use (4.9) with ux - vz - 1.
An analogous decomposition as of life expectancy,
may be effectuated for expected utility. This follows from
(4.7) which for the purpose of actually computing the several
components may be written as:
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whic}1, setting u(x) - x and vL - 1, may also be used to actu-
ally compute the components of life expectancy E.
An example of a general health index q(x) is:
(4.15) q(x) - e-rx~
specifying that the general health condition is at its maxi-
mum at age 0 and decreases at rate r, due to the increasing
prevalence of the other diseases. The utility u(x) of a dis-
ease free life time from 0 to x then becomes:
(4.16) u(x) - I e-rydy - T (1-e-rx)~
0
with u(x) ; l~r as x-~ ~.
Two examples of a(disease) specific health index
are:
(4.17a) qp(z) - e-sz
(4.17b) qD(z) - 1 - {1-qD(O)}e-sz
The index (4.17a) specifies a disease that becomes more serí-
ous with the duration of the disease. It implies that, from
the start of the disease at age x, the overall health index
at time y~ x is q(y) exp {-s(y-x)}. The index (4.17b) speci-
fies a disease that becomes less serious with the disease
duration. It implies that, at the start of the disease at age
x, the overall health index decreases by an amount q(x)qD(0),
while at time y~ x it decreases by an amount
q(i')qp(0) ex;~{-s(y-x)}.
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5. The interventioi; decision problem
From a decision maker's point of view the utility of
some individual's life time could differ from the individual's
own specification. For example: q(x) - exp {-r''ix-40j}, which
specifies that a disease free 40 year old subject has, to the
decision maker's point of view, maximal utility.
Another complication, when imaging a decision maker's
point of view, is that a decision maker will not consider one
subject at a time, but all subjects simultaneously. Assuming
identical utility functions, the problem of averaging the in-
dividual expected utility functions has its simplest represen-
tation in t'tie following expression for the average expected
utility:
Et, IEIU(X,W,J) iC - c}1 ,
w}iere C is a vector of (once measured) covariables (with a
given distribution over the population of subjects), supposed-
ly determining the time path of the rates al and a2. Average
expected utility (5.1) (and thus average life expectancy) may
be approximated by Monte Carlo simulation, as follows: make
a sufficient number of random drawings from the distribution
of C; determine the rates ~1 and a2; calculate the expected
utilities E'U(X,W,J)~c} from (4.9) or (4.14) for each vector
c drawn and average the expected utilities.
A more complicated but also more realistic aoproach
is as follows: al and a2 are constant in predetermined periods
(say 1,2,...), while the level of al and a,2 in period t depends
on the value of a vector of covariables measured at the start
of period t. The vector C in (S.1) then consists of vectors
of covariables supposedly measured at the starts of periods
1,2,... in a disease frec~ subject. This newly defined vector
C now determines the time path of al and ~2. The simulation
of average expected utility (5.1) is somewhat more complicated
as a dynamic element is introduced: the distribution of co-
variables evolves over time.
- 1 1 -
The intervenLion problem may be defined by means of
(5.1): choose the time t. x of screening the disease free
subjects (i.e. measure the relevant covariables, giving the
vector c, at age t) and take some appropriate action a(c) from
the set of possible actions, such that (5.1) is maximal. The
action a(c), which depends on c, is designed to influence c
to a new, more desired, value, giving a new time path for a 1
and ~2 from time t on.
A refinement may be accomplished by incorporating
the action a(c) as an argument in the utility funetion. After
all, the result of intervention may be the start of some form
of tr.eatment of a subject, meaning that the subject becomes
a patient for the rest of his disease free life. Analogously to
the disease specific health index qll(,), an action specific
health index qa(,) may be defined on which the general health
i.ndex c~(.) acts multiplicatively.
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